Novocure Stock Price, News & Analysis

Novocure (NASDAQ: NVCR) has announced that the results of its LUNAR phase 3 clinical trial in metastatic non-small cell lung cancer (NSCLC) will be unveiled at the 2023 ASCO Annual Meeting in Chicago from June 2 to June 6. This randomized, open-label study evaluates the safety and efficacy of Tumor Treating Fields (TTFields) combined with immunotherapies for patients progressing after platinum-based treatments. The trial has shown a statistically significant improvement in overall survival with the addition of TTFields. The data will be presented on June 6 at 11:09 a.m. CDT by Ticiana Leal, M.D., and includes among ten abstracts focused on TTFields therapy at the ASCO meeting. An investor event will also be hosted on the same day to discuss these findings.

Novocure (NASDAQ: NVCR) announced that 27 presentations on Tumor Treating Fields (TTFields) will be showcased at the AACR Annual Meeting 2023 from April 14 to 19 in Orlando, Florida. Research highlights include a comprehensive safety dataset of over 25,000 patients with glioblastoma, demonstrating the broad applicability and safety of TTFields therapy. A systematic review indicated improved overall survival in newly diagnosed glioblastoma patients treated with TTFields. Preclinical studies suggest that TTFields enhance the effectiveness of chemotherapy and may offer new treatment avenues for spinal metastasis and ovarian cancer. These findings underscore the potential of TTFields across various solid tumors, reinforcing Novocure's commitment to advancing cancer treatment.

Novocure (NASDAQ: NVCR) will announce its first quarter 2023 financial results on May 4, 2023, before U.S. market opening. A conference call is scheduled for 8:00 a.m. ET the same day to discuss the results for the three months ending March 31, 2023. Investors can access the call via a registration link. Novocure focuses on innovative therapies for aggressive cancers and has multiple ongoing clinical studies.

Novocure (NASDAQ: NVCR) has elected Kristin Stafford to its Board of Directors. Her extensive finance experience in the life sciences sector and role at Royalty Pharma are expected to support Novocure’s growth ambitions. Stafford, who has been with Royalty Pharma since December 2018, expressed excitement about joining Novocure during a pivotal time with key clinical trial readouts imminent. The company focuses on innovative therapies to extend survival for patients with aggressive cancers, with products approved for glioblastoma and pleural mesothelioma.

Virtual Incision Corporation has appointed Piet Hinoul as the new Chief Medical Officer, while Dmitry Oleynikov transitions to Chief Surgeon. Hinoul, with over 30 years in healthcare, previously headed medical affairs at Novocure (NASDAQ: NVCR) and has experience in surgical robotics at Johnson & Johnson (NYSE: JNJ). This leadership change aims to bolster Virtual Incision's efforts as it develops the MIRA Surgical System, the first miniaturized robotic-assisted surgery system designed for improved surgical efficiency. The company is focused on making every operating room RAS-ready, enhancing accessibility to advanced surgical technology.

Novocure (NASDAQ: NVCR) has announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program, collaborating with the American Association for Cancer Research. The initiative allocates over $1.5 million in research grants over three years to support innovative studies on Tumor Treating Fields (TTFields) therapy. This includes three grants of $350,000 for independent researchers and one $300,000 Career Development Award aimed at junior faculty. The application deadline is set for May 30, 2023. Novocure seeks to enhance understanding of TTFields mechanisms to improve cancer treatment options.

Optune is now a reimbursed treatment for newly diagnosed glioblastoma patients in France.

Novocure (NASDAQ: NVCR) announced that Optune is available alongside temozolomide (TMZ) for adult patients with glioblastoma (GBM). This follows its registration as a reimbursable product published in the Official Journal on February 28, 2023, effective March 15, 2023. Optune utilizes Tumor Treating Fields (TTFields) to disrupt cancer cell division and has treated over 27,000 patients worldwide. Clinical data from a phase 3 study showed median overall survival improved to 20.9 months with TTFields-TMZ versus 16.0 months with TMZ alone.

Novocure (NASDAQ: NVCR) has completed enrollment in the pivotal METIS study, which evaluates Tumor Treating Fields (TTFields) therapy post-stereotactic radiosurgery (SRS) for patients with brain metastases from non-small cell lung cancer (NSCLC). The study enrolled 270 adult patients and focuses on various endpoints, including time to first intracranial progression. Novocure anticipates final data in 2024, marking a significant period for the company and treatment of solid tumor cancers. This study is the fourth pivotal trial completed by Novocure in 17 months, with a steady flow of new data expected through 2024.